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ABSTRACT 
Objective: In the Brazilian public health system, sterile filtration is often used to prevent infections associated with platelet transfusion. The 
literature addressing this issue indicates that pathogen inactivation could be incorporated as an alternative to the development of individual tests 
and blood donor selection. The objective was to assess whether the use of platelets submitted to pathogen inactivation by photochemical methods 
could decrease the incidence of post-transfusion infections by viruses, bacteria or other pathogens compared to the use of platelet concentrate or 
platelets extracted by apheresis without photochemical treatment.  
Methods: A literature review from 1998 to 2015 was conducted. The scientific literature was surveyed using six electronic databases, two Internet 
search tools and a manual search of references, using specific search strategies for each database. The selected studies were assessed for quality 
according to a specific methodology. Data analysis was performed by observations made from the efficacy of the methods.  
Results: From a detailed analysis of 426 articles retrieved, 10 articles were selected for this review. Among the selected studies, seven studies were 
clinical trials, and three studies were systematic reviews in combination with meta-analysis. The outcomes analyzed included the reduction of the 
residual risk in pathogen transmission, mortality, occurrence of hemorrhagic events, corrected count increment (CCI) after 1 h, CCI after 24 h, and 
transfusion reactions.  
Conclusion: Differences were found in the quality of the included studies. Systematic reviews conducted on this topic, in alliance with political, 
social and administrative factors, will aid decision makers regarding its incorporation into the Brazilian Health System. 
Keywords: Blood Platelets, Platelet Transfusion, Platelet Transfusion/methods*, Riboflavin, Ultraviolet Rays, Photosensitizing Agents, Platelet 
Transfusion/adverse effects 
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INTRODUCTION 
Blood and blood component transfusions are important procedures 
in modern therapeutics; however, like most treatments, they may 
cause acute and late complications. Moreover, such procedures may 
also serve as vehicles for infectious agents. According to the World 
Health Organization (WHO) [1] the transmission of infectious agents 
through blood or blood components represents a focal point for 
transfusion risk. In the Brazilian public health system, transfusion is 
a high-cost practice associated with voluntary donation and cutting-
edge technology. These features necessitate the rational use of blood 
components, always considering the safety of the donor and the 
recipient, and the availability of access [2]. 
In Brazil, besides donor selection, screening tests for human 
immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), 
hepatitis C virus (HCV), syphilis, human T-lymphotropic viruses I 
and II (HTLV I-II), antibody against hepatitis B virus (HBV) core 
antigen (Anti-HBc) and Trypanosoma cruzi are performed on 100% 
of the blood bags [3]. In addition to the disposal of blood bags with 
the direct or indirect identification of pathogens, technological 
developments in chemotherapy have incorporated novel techniques 
that aim to increase transfusion safety, once immunology is a 
medical biotechnology area in constantly development [4]. 
Regarding the prevention of infections associated with platelet 
transfusion, sterile filtration to avoid clots and microaggregates is a 
prominent standard practice in the Brazilian public health system 
[3]. However, this technique does not a goal to eliminate pathogens 
and the literature addressing this issue highlights the need for 
identification and/or removal of emerging pathogens and zoonotic 
viruses [5]. Thus, pathogen inactivation has been proposed as a 
complementary approach to reduce residual risk of infection by a 
widely knowed microorganism and mainly when individual tests 
and blood donor selection are not enough [6, 7]. 
The techniques for pathogen inactivation can be used on several 
blood products. The methods applied in platelet concentrates are 
based on the assumption that the photochemical inactivation of 
pathogens nucleic acids may ensure safer transfusions.  
These techniques were initially developed in the 1990s and, 
according to Kaiser-Guignard and colleagues [8], the three most 
commonly used technologies are the amotosalen/ultraviolet A 
(amotosalen/UVA) (Intercept® Blood System–Cerus, Europe, BV, 
Amersfoort, The Netherlands), riboflavin/ultraviolet A and 
ultraviolet B (riboflavin/UVA-UVB) (Mirasol® PRT) and ultraviolet 
C (UVC) (Theraflex-UVC®). 
The present study aimed to identify and classify the available 
evidence on the efficacy of methods that aim to reduce the residual 
risk of pathogen transmission in platelet transfusions. 
MATERIALS AND METHODS  
The literature review sought to answer the following question: 
Compared to platelet concentrate or platelets extracted through 
apheresis without photochemical treatment, does the use of 
platelets inactivated by photochemical methods such as Intercept®, 
Mirasol® or Theraflex® decrease the incidence of post-transfusion 
infections by viruses, bacteria or other pathogens? 
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Additionally, the effects of the pathogen inactivation methods on the 
preservation of the blood components were assessed regarding the 
maintenance of transfusion efficacy compared to components that 
did not undergo photochemical treatment and with respect to 
ensuring the safety of the transfusion recipients. 
The database searches were guided by questions according to a PICO 
question, which considered patients requiring platelet transfusion 
and intervention as treatment of platelets using amotosalen-HCl in 
combination with UVA radiation (Intercept® Blood System) or 
riboflavin in combination with UVA+UVB (Mirasol® PRT) or UVC 
radiation (Theraflex®). The comparison was between platelet 
concentrate and platelets extracted by apheresis without 
photochemical treatment. The observed outcomes were a reduction 
of the residual risk of pathogen transmission, mortality, occurrence 
of hemorrhagic events, duration of the hemorrhagic event, platelet 
count before transfusion, corrected count increment (CCI) after 1 h, 
CCI after 24 h, transfusion reactions. Randomized clinical trials and 
systematic literature reviews were selected and assessed. 
Studies excluded from this review were those that concerned a 
matrix other than the one of interest (platelets), studies that used 
the technology during the blood product production process, 
experimental in vitro studies, studies that lacked an abstract and/or 
that used a technology different from the ones of interest, single-arm 
and/or open clinical trials, and studies that used a limited 
population or that did not evaluate any of the outcomes of interest. 
The research was performed from August to December 2015. No 
temporal limits were set, thus all studies found in the investigated 
databases at the time of data collection were considered. 
Randomized controlled clinical trials that assessed pathogen 
inactivation methods regarding the outcomes of interest, as well as 
systematic reviews and meta-analyses, were selected to gather 
scientific evidence on the proposed technologies. 
Descriptors, keywords and Medical Subject Headings (MeSH) terms 
were used to define the searches in the following electronic 
databases: Medline (via PubMed), Cochrane Library (via Bireme), 
Centre for Reviews and Dissemination (CRD), LILACS (via BVS) and 
Science Direct. Searches were performed with a combination of the 
terms for platelets and the terms of one of the technologies, 
according to the corresponding database. An additional search was 
performed in the reference list of the selected articles to find studies 
that were not identified in the electronic databases. A comparison of 
the search results in the different databases was performed to 
eliminate duplicates. 
Regarding data collection and data mining, the initial stage, 
consisting of study selection, was performed through title and 
abstract reading by two reviewers (P. M. V. and R. R. A. F.). Next, the 
selected texts were read in full, and those that met the selection 
criteria were included. When the first two reviewers disagreed, a 
third reviewer (G. B. G. M.) made the final decision. All studies were 
subjected to the Oxford Centre for Evidence-Based Medicine (CEBM) 
Evidence Level [9]. 
After a full reading, the articles included were detailed in tables 
wherein the outcomes and the main findings were highlighted. The 
methodological limitations that might have compromised the 
strength of the results and conclusions were assessed. The CEBM 
recommendations were used as parameters. All studies were 
classified according to their methodological design. The associated 
recommendation level considered the quality and reliability of the 
information provided. 
RESULTS  
In the analyzed literature, the amount of evidence varied according 
to the type of pathogen inactivation technology and the blood 
component. No evidence was found for Theraflex UVC®. Among the 
technologies available for the microbial treatment of platelets, 
Intercept® (Amotosalen) was the most extensively studied, followed 
by Mirasol®. 
Fig. 1 shows the selection process of the eligible studies. Out of 426 
citations, six studies were included. Additionally, four studies 
identified from cross-references were included, totaling 10 studies 
that comprised this review. Among the included studies, seven were 
clinical trials (one associated with Mirasol® and six with 
Intercept®) and three were systematic reviews in combination with 
meta-analysis associated with Intercept®, totaling nine studies on 
Intercept® and one on Mirasol®. 
 
 
Fig. 1: Flowchart of results search and selection 
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For the Intercept® technology, which was applied when platelets 
were therapeutically recommended, three meta-analyses and six 
randomized clinical trials were obtained from the literature. table 1 
shows the main features of the clinical trials. 
 
Table 1: Outcomes of the selected clinical trials 









































































































































































































































Source: Developed by the authors; NA: Not available 
 
The outcomes evaluated in the clinical trials were heterogeneous. 
Janetzko and colleagues [10] and Lozano and colleagues [11] 
observed differences in the platelet corrected count increment (CCI) 
among the groups; however, according to the authors, these 
differences were not significant and thus were not clinically 
relevant. Alternatively, van Rhenen [15] and Simonsen [13] found 
that the 1-h CCI levels were significantly lower in patients who 
received platelets subjected to the intervention compared to 
patients who received control platelets (P=0.03). 
Janetzko and colleagues [10] reported that the most common 
adverse events included fever, diarrhea, vomiting, and epistaxis, 
with at least one adverse event noted by each participant. The 
differences in the occurrence of severe adverse events between the 
intervention and control groups were not statistically significant. In 
contrast, Lozano [11] considered a positive blood culture as an 
adverse event and noted that 6.7% of the intervention group 
exhibited this event, compared with 1.9% in the control group. The 
other adverse events observed were fever, chills, nausea and 
cutaneous rash. In the study by van Rhenen [15], the most frequent 
adverse events were epistaxis, gingival bleeding, bleeding at the 
injection site and purpura; no significant differences were observed 
in the frequency of severe adverse events between the intervention 
and control groups. 
The clinical trial performed by McCullough and colleagues [12] 
evaluated the percentage of patients with different bleeding levels 
according to the scale used by the WHO, which ranges from 0 to 5. 
The frequency of grade 2 hemorrhage was the primary outcome of 
the study; however, other bleeding levels were also assessed (grade 
3 or 4 bleeding occurred in 4.1% of the intervention group and in 
6.1% of the control group, with no statistical significance).  
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Moreover, patients in the intervention group were observed to have 
decreased the 1-h and 24-h CCIs and exhibited a shorter interval 
between transfusions. According to the authors, these differences 
would be minimized in clinical practice as the methodology 
performed for pathogen inactivation in this study resulted in platelet 
loss. A lower rate of platelet viability was also reported in the 
intervention group and thus, the frequency of platelet refractoriness 
was higher in this group. 
In the study of van Rhenen [15], the need for a greater number of 
transfusions in the intervention group patients compared to the 
control group was reported (mean: 7.5±5.8 and 5.6±5.5, 
respectively). The authors suggested that this phenomenon was 
caused by the loss of platelet content in the samples subjected to 
the pathogen reduction technology, which occurred in two ways: 
(a) the need for samples used to verify the amotosalen 
concentration and (b) the loss of platelets during transfusion 
through the use of the technology. The crossover design was 
adopted in the clinical trial performed by Simonsen [13]. In this 
study, the authors did not observe the non-inferiority of the 
pathogen inactivation method in comparison to the platelet 
concentrate that was not subjected to the technology. In addition 
to the outcomes depicted in table 2, this study also evaluated 
changes in the level of bleeding events according to the WHO scale 
and observed no significant differences. 
Our search revealed that the studies with the highest level of 
evidence were systematic reviews with a meta-analysis. Due to the 
heterogeneity of the outcomes addressed, it was not possible to 
synthesize the information into a single-table format. Only the 
outcomes of the 1-h CCI and the 24-h CCI were addressed by all 
studies and are thus depicted in table 3. 
 
Table 2: Description of features in the selected studies 
Study Study population Method of platelet 
collection 
Outcomes Observed results Source 




Systematic review/NA NA Number, type and severity of 
bleeding, mortality from all 
causes, adverse events, 
corrected count increment, 
need for and interval of red 
blood cell and platelet 
transfusion 
Nine clinical trials evaluated 
the effectiveness of 
Intercept®. 
No evidence was reported of 
differences in mortality, 
“clinical significance”, “severe 
bleeding”, transfusion 
reactions or adverse events. 
Some benefits of the standard 
platelets were observed with 








Meta-analysis/NA NA Corrected count increment 
after 1 hour and 24 h, interval 
between transfusions, 
bleeding odds ratio 
Five clinical trials found. High 
variation of results among the 
randomized clinical trials. 
Inactivated blood showed 
lower corrected increment 
count (24-h CCI); however, this 
finding was not associated 
with differences in the 
bleeding odds ratio. A higher 
interval between transfusions 
was observed in patients who 
received platelets that were 
















Apheresis Count increment after 1 hour 
and 24 h, acute transfusion 
reactions, adverse events, 
occurrence of bacteremia 
associated with transfusion, 
antibody formation against 
amotosalen 
 
Photo chemically treated 
platelets and standard 
















Proportion of patients with 
grade 2, 3 or 4 bleeding, 
number of days with grade 2 
bleeding, 1-h and 24-h CIs and 
CCIs, number of days until new 
platelet transfusion, number of 
platelet transfusions, number 
of red blood cell transfusions, 
adverse events, development 
of antibodies against the 
neoantigen amotosalen 
 
The 24-h CCI was significantly 
lower in patients who received 
blood subjected to pathogen 
inactivation; however, no 
significant changes were 
observed with regard to 
bleeding events. An episode of 
alloimmunization was 
observed in the intervention 











trial, phase III/671 
blood cancer pediatric 
Apheresis Primary outcome: proportion 
of patients with grade 2 
bleeding according to the scale 
used by the World Health 
Organization (WHO); 
Patients who received platelets 
treated with Intercept® 
exhibited lower CCI levels and 
shorter intervals between 
transfusions. 
[12] 
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and adult patients with 
thrombocytopenia 
secondary outcomes: 
proportion of patients with 
grade 3 or 4 bleeding, duration 
of grade 2 bleeding, 1-h and 
24-h CIs and CCIs, interval 
between transfusions, number 
of platelet transfusions, 
incidence of platelet 
refractoriness, and number of 
red blood cell transfusions. 
Safety outcomes: number of 
transfusion reactions and 


















CCI at 1 h, CI at 1 h, interval 
between transfusions, 
frequency of acute transfusion 
reactions, changes in bleeding 
severity according to the WHO 
scale 
CCI at 1 h, CI at 1 h and interval 
between transfusions were 
significantly lower in the 
intervention group. 
Transfusion reactions 
occurred at a significantly 










cancer patients with 
thrombocytopenia 
Collected with CS-3000 
and leukoreduced by 
filtration 
Hemostasis evaluated by 
duration of percutaneous 
bleeding, platelet count, 
increments, CCIs, interval 




Average bleeding time in PCT 
(29.2 min) and reference (28.7 
min) groups. 
Mean 1-h CCI was 41.9 X109 
and 52.3 X109
[14] 
for PCT and 
reference groups, respectively. 
Time to the next transfusion 
was 2.9 d and 3.4 d for PCT 
and reference groups, 
respectively. Clinical 






Meta-analysis/NA NA Hemostatic Efficacy Four clinical trials were 
analyzed. 
Pathogen reduction led to a 
reduction in the 1-hour CCI; 
significant reduction in the 24-
h CCI; increase in platelet 



















CCI at 1 h, CCI at 24 h, number 
of transfusions, interval 
between transfusions, clinical 
hemostasis before and after 
transfusions, amount of red 
blood cell transfusions, 
refractoriness, 
alloimmunization, adverse 
events, occurrence and 
severity of bleeding 
Patients in the intervention 
group had significantly lower 
1-h CCI and needed more 
platelet transfusions. 
Hemostatic scores, cases of 
refractoriness and number of 
red blood cell transfusions 
were similar among groups. No 




Source: [9-17]. NA: Not available 
 
The other outcomes of lesser importance are briefly described in the 
following paragraphs. 
Butler et al., 2013 [16] 
This study evaluated the efficacy of platelet concentrates subjected to 
pathogen reduction by both Intercept® and Mirasol® in preventing 
hemorrhages. Only clinical trials with any type of patient who required 
transfusion were considered. The studies comparing the use of 
Intercept® with the standard intervention were evaluated. 
Eight clinical trials were found that examined the outcome of “any 
bleeding event”– regardless of the time or intensity. A meta-analysis 
was performed with a subgroup of studies that evaluated a single 
transfusion with a 48-hour follow-up (3 studies) and studies that 
evaluated multiple transfusions with a 7-day follow-up (5 studies). 
The pooled results for the first group showed no increased risk of 
bleeding associated with the intervention (RR 0.86 [0.63–1.19]; CI 
95%; P=0.48 and I2=0%). Regarding the arm that received the 
intervention, more bleeding was found (RR 1.07 [1.01–1.13]; CI 
95%; P=0.007 and I2=59%). 
For the outcome of the clinically significant bleeding event, 6 clinical 
trials were found: 2 trials addressed single transfusions, and 4 trials 
addressed multiple transfusions. The meta-analysis performed only 
for the latter group that had a 7-day follow-up, showed no significant 
difference between the study arms (RR 1.04 [0.91–1.18]; CI 95%; 
P=0.58 and I2
Regarding the outcome of severe bleeding, a meta-analysis was 
performed only for the subgroup of multiple transfusions with a 7-
day follow-up. In the pooled results, no differences between the 
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Table 3: Outcomes of the selected clinical trials 

























































































































































































NA 29.2±1.6 10.4±4.9 
 






































Source: [9-14] (I vs. C): Intervention vs. Control. NA: not available. *Results of grade 2 or higher bleeding (according to the World Health 
Organization classification, 2003) 
 
Concerning mortality from all causes, a meta-analysis was 
performed only for studies with a 12-week follow-up (6 clinical 
trials). In this case, no difference was observed between the 
intervention arms (RR 0.73 [0.41–1.29]; CI 95%; P=0.28 and 
I2=0%). For mortality caused by hemorrhage and by infection, 
meta-analysis was performed with the same studies, and no 
differences between the arms were observed in any case, with 
the following results: (RR 1.03 [0.28–3.72]; CI 95%; P=0.97 and 
I2=0%) and (RR 0.58 [0.25–1.39]; CI 95%; P=0.22 and I2
A meta-analysis of 4 clinical trials was performed for bleeding 
events. Due to differences among the findings, the hypothesis of 
homogeneity was rejected. Moreover, I
=0%), 
respectively. 
Cid et al., 2012 [17] 
This study aimed to evaluate the use of Intercept® as a method of 
pathogen inactivation, with a focus on the following outcomes: 1-h 
and 24-h CCI, in addition to the odds ratio (OR) for bleeding events. 
2 showed moderate 
discrepancy among the results (I2
Thus, the study examined 8 subgroups of constructed studies 
wherein the assumption of homogeneity was not rejected in the 
following 5 results: double-blind studies with ABO compatibility, 
studies with 5-day storage period for platelets, studies with 
high-quality Jadad scores [19] and studies that used the WHO 
bleeding scale.  
=53%; CI 95%, 0%-83%).  
The use of Intercept® was not statistically associated with an 
increase in the OR associated with bleeding events compared to 
the non-intervention in any the subgroup analyses. The results 
of these five subgroups are shown in table 4. 
 
Table 4: Results of bleeding events with Intercept® for the study subgroups 
Study subgroup Number of studies  OR [CI 95%] P-value for Q test I2 Source (%) 
Double blind 4 [1-4] 0.97 [0.75–1.27] 0.58 0 [10–12,15] 
ABO compatibility 2 [1,4] 0.84 [0.48–1.45] 0.76 0 [10–12,15] 
5-day storage 3[1-3] 1.04 [0.78–1.39] 0.26 21 [10,12,15] 
High Jadad quality (3-5) 4 [1-4] 0.97 [0.75–1.27] 0.58 0 [10–12,15] 
WHO scale 3 [2-4] 0.95 [0.72–1.25] 0.44 0 [10–12] 
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Vamvakas, 2011 [18] 
This systematic review with a meta-analysis of 4 clinical trials used the 
main outcomes of the 1-h and 24-h CCIs. These outcomes were also 
reported by all other systematic reviews and are depicted in table 5. 
Regarding the Mirasol® technology, only one clinical trial was 
obtained from the literature on the use of this technology as 
recommended for platelets. The study evaluated a group of 118 
patients (60 in the intervention group and 58 in the control group) 
that received a total of 541 transfusions during 28 d. The outcomes 
measured are presented in table 5. 
The study of Cazenave [20] did not report non-inferiority of platelets 
treated by Mirasol® compared to platelets that were not subjected 
to this method with regard to the primary outcome analyzed, the 1-h 
CCI. The result was similar for the secondary outcomes. One hour 
after the transfusions, 71.3% of transfusions were successful in the 
intervention group compared with 84.1% in the control group. After 
24 h, this result was 58.9% and 68.1%, respectively. 
 
Table 5: Description of the outcomes found in the meta-analyses 
Study 1-h CCI (x103 24-h CCI (x10) [CI 95%] Difference among the means 3 Source ) [CI 95%] Difference among the means 
Butler, 2013  -0.89 [-2.35; 0.58] -1.96 [-3.24;-0.68] [16] 
Cid, 2012  1.4 [-2.69; 0.11] 3 [-3.69; 2.32] [17] 
Vamvakas, 2011  3.15 [1.85; 4.45] 3.5 [2.06; 5.0] [18] 
Source: Developed by the authors 
 
To evaluate the method’s safety, the occurrence of infections as 
adverse events was assessed. Through this analysis, no significant 
differences were observed in the proportion of patients with one or 
more infections when the intervention and control groups were 
compared. Mortality was included as a severe adverse event; 
however, mortality data were not presented separately. In the 
intervention group, 13 patients (23.2%), compared to 11 patients 
(20.4%) in the control group, had at least one severe adverse event. 
The results showed that the patients who received platelets 
subjected to this technology exhibited inferior evaluations in regard 
to the analyzed outcomes; however, this finding was not clinically 
significant. Regardless, no riboflavin reference concentration was 
found to be recommended for this use, thus it is not possible to 
conclude whether the concentration that was able to maintain 
platelet viability is the same concentration that should be used for 
pathogen inactivation. 
DISCUSSION 
The studies showed several types of heterogeneity in their 
methodologies, traversing the domains of clinical, methodological 
and statistical diversity. 
Some of the observed heterogeneity was associated with the 
population included in the study, the variety of the observed 
outcomes and differences in the methodology and parameters used 
to measure the outcomes.  
Moreover, it was possible to observe that no gold standard existed 
for the outcomes or for measuring the outcomes, with no gold 
standard to determine the efficacy and safety, creating obstacles for 
the comparison of the data collected and generating considerable 
heterogeneity among the studies. 
Limitations were also found in the analyzed studies. Among these 
limitations, the following may be highlighted: (a) inadequate 
amotosalen concentration use, with some studies using the technology 
component solution at concentrations below those recommended by 
the Food and Drug Administration (FDA); (b) inaccuracy or omission 
of the method for obtaining the blood component, without any 
specification of whether it was through apheresis or buffy-coat and/or 
the amotosalen dose used; and (c) a lack of outcome standardization, 
wherein each study evaluated efficacy and safety in a specific manner 
instead of using a common manner. 
Studies by Simonsen [13], Janetzko [10], McCullough [12] and van 
Rhenen [15] reported the use of amotosalen in a concentration 
significantly lower than that recommended by the FDA (150 µM vs. 3 
mM). In the study of Lozano [11], the concentration used was not 
described. Notably, the main aim of that study was to test the safety 
of the pathogen inactivation method and thus it would have been 
germane to discuss the differences between the concentrations 
tested and the one that was approved. This observation may 
represent an important confounding variable because it is not 
possible to assure that the low occurrence of adverse events and 
platelet quality would be maintained had the approved 
concentration been used instead, which is 20 times the 
concentration tested. 
CONCLUSION 
The present study aimed to evaluate, from a comprehensive review 
of the scientific literature, the evidence demonstrating the potential 
benefits and risks of the large-scale use of platelets subjected to 
pathogen inactivation methods. The scope of the literature was 
distinctive. Evidence for employing the amotosalen (Intercept®) 
technology was more robust and was supported by a higher number 
of studies. Overall, the studies aimed to assess the efficacy and safety 
of the transfusions of platelets previously treated with pathogen 
inactivation methods in comparison to untreated platelets. The 
outcomes in reference to platelet efficacy were associated, directly 
or indirectly, with the ability of the method to maintain the viability 
of this blood component. Concerning the safety aspect, the 
observations were similar to those regarding the efficacy, always 
referring to the blood component attributes. 
The results of the studies predominantly found no significant 
differences of the transfusion efficacy between the intervention and 
control arms, particularly in the case of outcomes associated with 
hemorrhagic events. 
Notably, the use of Intercept® resulted in a reduction in the number 
of platelets and the volume to be transfused. Moreover, it is 
currently unclear whether the relationship between the amotosalen 
concentration and platelet reduction is dose-dependent. Amotosalen 
was found to have been used at concentrations significantly lower 
than the dose approved for clinical practice by the FDA; thus, if a 
dose-dependent relationship is eventually detected, it is possible 
that the use of amotosalen at the recommended concentration may 
cause a significant reduction in the number of platelets, capable of 
interfering with the efficacy of the clinical procedure and with the 
need for more donations. 
Ultimately, the studies showed supportive results concerning 
efficacy; however, results addressing the inactivation of pathogens 
were lacking. Thus, the data are insufficient to conclude that such 
methods exhibit clinical superiority in regard to their primary 
purpose: to prevent post-transfusion infections. 
The currently available evidence supports the conclusion that the 
methods that actually inactivate pathogens in blood components are 
based on in vitro studies only. However, even if the evidence exists 
from in vitro studies, the epidemiological data showing the efficacy 
of a particular method against a specific pathogen are the most 
important type of evidence in clinical practice [8]. 
Most of the clinical trials assessed were non-inferiority trials, i.e., 
they sought to show that the quality of platelet concentrates that 
were subjected to pathogen inactivation was not inferior to the 
control. In contrast, the few studies that assessed bacteremia and 
sepsis after transfusion as adverse events found no such events in 
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both the intervention and control arms. These findings do not permit 
us to conclude that the technologies herewith are effective for 
pathogen inactivation; thus, based on this weak evidence, our 
recommendation is that these technologies not be incorporated into 
the Brazilian Unified Health System. 
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